23 Results for "

MEI1

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "MEI1" in MCE Product Catalog:

10
10 Publications Verification
Cat. No.: HY-15227
CAS No.: 1338466-77-5
Purity:  99.00%
EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia [1] .
10
10 Publications Verification
Cat. No.: HY-15227A
CAS No.: 1380316-03-9
Purity:  99.46%
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia [1] .
4
4 Cited Publications
Cat. No.: HY-15222
CAS No.: 1271738-62-5
Purity:  99.81%
Research Areas:  

Cancer

Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) [1].
Cat. No.: HY-156794
CAS No.: 2412555-70-3
Purity:  99.88%
Synonyms: DSP-5336
Research Areas:  

Cancer

Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [1] .
Cat. No.: HY-172416
CAS No.: 2939850-17-4
Synonyms: ZE63-0302
Research Areas:  

Cancer

Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia [1].
Cat. No.: HY-134258
CAS No.: 446306-43-0
Purity:  98.76%
Target:  

HOXA

Research Areas:  

Cardiovascular Disease Others Cancer

MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer [1].
Cat. No.: HY-RS08319
Research Areas:  

Others

MEI1 Human Pre-designed siRNA Set A contains three designed siRNAs for MEI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS27893
Research Areas:  

Others

Mei1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mei1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-132870
CAS No.: 2761326-86-5
Purity:  99.33%
Target:  

HOXA

Research Areas:  

Others

MEIS-IN-2 is a myeloid ecotropic viral integration site 1 (MEIS1) inhibitor.
Cat. No.: HY-RS21374
Research Areas:  

Others

Mei1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mei1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS08325
Research Areas:  

Others

MEIS1 Human Pre-designed siRNA Set A contains three designed siRNAs for MEIS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-155797
CAS No.: 2654081-27-1
Synonyms: (S)-JNJ-75276617; (S)-Menin-MLL inhibitor 24
Target:  

Drug Isomer HOXA

Research Areas:  

Cancer

(S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib (HY-148669). (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia [1].
Cat. No.: HY-160018
CAS No.: 2163769-52-4
Research Areas:  

Cancer

BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models [1].
Cat. No.: HY-178172
AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent AF9/ENL and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC50 = 1.5 μM), AF9-AF4 (IC50 = 1 μM), ENL-AF4 (IC50 = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia [1].
Cat. No.: HY-RS25706
Research Areas:  

Others

Meis1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Meis1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-155526
CAS No.: 3049681-20-8
Target:  

Histone Demethylase

Research Areas:  

Cancer

FY-21 is a selective inhibitor of LSD1 (IC50=340 nM), with anti-proliferation and anti-colony formation activities. FY-21 enhances p53 expression, down-regulates HOXA9 and MEIS1 expression. FY-21 also induces leukemia cell differentiation to exhibts antitumor activity [1].
Cat. No.: HY-15222A
Research Areas:  

Cancer

Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 dihydrochloride downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) [1].
Cat. No.: HY-RS19217
Research Areas:  

Others

Meis1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Meis1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-186043
CAS No.: 2654080-48-3
Research Areas:  

Metabolic Disease Cancer

Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes [1].
Cat. No.: HY-186044
CAS No.: 2654078-52-9
Research Areas:  

Metabolic Disease Cancer

Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes [1].